When a child develops a brain tumor, early diagnosis is essential. Alan Cohen, M.D., director of pediatric neurosurgery at Johns Hopkins Children’s Center, shares the most common signs and symptoms ...

The TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for a protein that inhibits the development and ...

Start here FELLSMERE, Fla. – The largest frog leg festival in Florida is back again, serving up thousands of pounds of frog legs and gator. The 34th annual Fellsmere Frog Leg Festival will kick ...

Macroprolactinoma is a type of pituitary tumor that leads to excess production of the hormone prolactin. This type of tumor is larger than a microprolactinoma but smaller than a giant prolactinoma.

Brain cancer and other nervous system cancers have a 33.4% five-year survival rate. In adults, brain tumors rarely begin in the brain — when they do, they're known as primary brain cancers.

Mark Agulnik, MD, discusses the efficacy and adverse events in the DeFi trial for patients with desmoid tumors given nirogacestat. Mark Agulnik, MD, professor of Clinical Medicine, Vice Chair for ...

For 3 out of every hundred people with cancer, the primary site of cancer isn't found. When this is the case, the tumor is usually referred to as a metastatic cancer of unknown primary origin. With ...

Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors, IM-1021, a ROR1 ADC with ...

First and foremost, it was able to achieve FDA approval of its lead drug OGSIVEO [nirogacestat] for adult patients with progressing desmoid tumors who require systemic treatment. This company was ...

1Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany. 2Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer ...

Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the ...